Premarket Earnings Report as of March 31, 2022: WBA, AFMD, NNOX, RNLX, PDSB, JFIN, PLX, MINM, BIOC, CLSN


JThe following companies are expected to report earnings before the market opens on 3/31/2022. See our results calendar for a full list of expected results releases.

Walgreens Boots Alliance, Inc. (WBA) reports for the quarter ending Feb. 28, 2022. The drugstore company’s consensus earnings-per-share forecast from the 7 analysts who track the stock is $1.38. This value represents a decrease of 1.43% compared to the same quarter last year. Over the past year, the WBA has exceeded expectations every quarter. The highest was in the 4th calendar quarter where they beat consensus by 24.44%. Zacks Investment Research reports that the 2022 price-to-earnings ratio for WBA is 9.51 versus an industry ratio of 4.60, implying that they will have higher earnings growth than their competitors in the same industry.

Affimed NV (AFMD) releases a report for the quarter ending December 31, 2021. The consensus earnings per share forecast for the biomedical company (gene) from the 4 analysts who track the stock is -$0.17. This value represents an increase of 15.00% compared to the same quarter last year. The past two quarters, AFMD has had negative earnings surprises; the last report they missed by -30.77%. Zacks Investment Research reports that the 2021 P/E ratio for AFMD is -8.73 vs an industry ratio of -18.50, implying they will have higher earnings growth than their competitors in the same sector.

NANO-X IMAGING LTD (NNOX) reports for the quarter ending Dec. 31, 2021. The technology services company’s consensus earnings-per-share forecast from the 2 analysts who track the stock is -$0.37. This value represents an increase of 19.57% compared to the same quarter last year. The “days to cover” for this stock exceeds 11 days. Zacks Investment Research reports that the 2021 P/E ratio for NNOX is -8.41 versus an industry ratio of 16.00.

Renalytix AI plc (RNLX) releases a report for the quarter ending December 31, 2021. The information technology services company’s consensus earnings per share forecast from the 3 analysts who track the stock is -$0.17. This value represents a decrease of 41.67% compared to the same quarter last year. Zacks Investment Research reports that the 2022 price-to-earnings ratio for RNLX is -10.97 versus an industry ratio of 46.10.

PDS Biotechnology Company (PDSB) reports for the quarter ending Dec. 31, 2021. The consensus earnings per share forecast for the biomedical company (gene) from the top analyst tracking the stock is -$0.23. This value represents a decrease of 43.75% compared to the same quarter last year. The past two quarters, the PDSB has had negative earnings surprises; the last report they missed by -9.09%. Zacks Investment Research reports that the 2021 price-to-earnings ratio for PDSB is -7.30 vs. an industry ratio of -18.50, implying they will have higher earnings growth than their competitors in the same industry .

Jiayin Group Inc. (JFIN) reports for the quarter ending Dec. 31, 2021. The internet software company’s consensus earnings-per-share forecast from the top analyst tracking the stock is $0.32. This value represents an increase of 33.33% compared to the same quarter last year. Over the past year, JFIN has exceeded expectations for the other three quarters. Zacks Investment Research reports that the 2021 P/E ratio for JFIN is 2.32 versus an industry ratio of -84.60, implying that they will have higher earnings growth than their competitors in the same industry.

Protalix BioTherapeutics, Inc. (PLX) reports for the quarter ending December 31, 2021. The consensus earnings per share forecast from the 1 analyst tracking the stock is -$0.11. PLX reported earnings of $0.03 per share for the same quarter a year ago; representing a decline of -466.67%.PLX missed consensus earnings per share in the 2nd calendar quarter of 2021 by -212.5%. Minime, Inc. (MINM) reports for the quarter ending December 31, 2021. The network company’s consensus earnings per share forecast from the 2 analysts who track the stock is -$0.04. This value represents a decrease of 33.33% compared to the same quarter last year. MINM missed consensus earnings per share in the 3rd calendar quarter of 2021 by -183.33%. Zacks Investment Research reports that the price-to-earnings ratio for MINM is 0.00 versus an industry ratio of 4.90.

Biocept, Inc. (BIOC) reports for the quarter ending Dec. 31, 2021. The medical services company’s consensus earnings-per-share forecast from the top analyst tracking the stock is -$0.16. This value represents a decrease of 214.29% compared to the same quarter last year. Zacks Investment Research reports that the 2021 P/E ratio for BIOC is -24.78 versus an industry ratio of 7.90.

Celsion Corporation (CLSN) reports for the quarter ending December 31, 2021. The consensus earnings per share forecast for the biomedical company (gene) from the 2 analysts who track the stock is -$0.90. This value represents a decrease of 20.00% compared to the same quarter last year. Over the past year CLSN and has exceeded expectations for the other three quarters. Zacks Investment Research reports that the 2021 P/E ratio for CLSN is -1.28 versus an industry ratio of -18.50, implying that they will have higher earnings growth than their competitors in the same industry.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


nasdaq

Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button